KURA · Kura Oncology, Inc.
$10.60
-0.02 (-0.19%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$957.22M
Shares
88.96M
Volume · Oct 5
1.29M
Avg daily vol (3M)
1.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.62
Open$10.73
Day$10.29–10.80
52W close$7.40–13.59
Avg vol 30d2.0M
Short int14.8M · 16.7% float · 8.8d
Short vol49%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 12, 2026
call held Mar 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+16.5%
Trailing year
Short interest
16.7%
Latest settlement · 8.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
−5%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
52%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
+16%
trailing
YTD return
+2%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Flat
2 of 222 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$1.3M over 90 days · 80% sells
Short interest
Rising
16.66% of float · ▲ +10.5% MoM · 8.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
222 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+25%
Y/Y
EPS growth
−57%
Y/Y
Free cash flow
$-70.7M
Balance sheet
$139.4M
net cash
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
52%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Flat
2 of 222 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$1.3M over 90 days · 80% sells
Short interest
Rising
16.66% of float · ▲ +10.5% MoM · 8.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
222 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $11 · 52%
Range high $14
vs 200-day avg +8%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| New patient starts (NPS) | 115 | 2Q 2026 | — |
| Total prescriptions (TRx) | 250 | 2Q 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KURA
this stock
Kura Oncology, Inc.
|
$957.22M | +2.2% | +25.2% | — | 16.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KURA | +0.1% | -19.9% | +16.2% | -0.8% | +2.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.1% | -20.5% | +4.6% | -2.4% | -11.4% |